Company Overview
Snapshot
Founded in January 2002 by Dan Hashimshony, Dune Medical Devices operated with 11–50 employees. The company raised a total of $53.8M across 6 funding rounds from 5 investors. Dune Medical Devices was acquired by Dilon Technologies in April 2020.
Business overview
Dune Medical Devices specializes in developing tissue characterization technology for real-time cancer detection, primarily serving surgeons and radiologists. Its core product, the MarginProbe System, utilizes a Fringe Field Sensor to assess excised tissue margins during surgery, particularly for breast cancer. The company was also developing a smart biopsy system for breast tissue, expanding its surgical oncology portfolio. Dune Medical Devices operates within the Health Tech & Life Sciences sector, focusing on medical devices and diagnostics.
Strategic signal
In April 2020, Dune Medical Devices was acquired by Dilon Technologies. This acquisition signifies a strategic consolidation within the medical device industry, integrating Dune Medical's real-time cancer detection technology into a larger portfolio and potentially expanding its market reach and application.
Company Intelligence Q&A
- When was Dune Medical Devices acquired?
- Dune Medical Devices was acquired by Dilon Technologies in April 2020.
- What is the primary function of the MarginProbe System?
- The MarginProbe System provides real-time cancer detection in the operating room by assessing the margin of excised tissue using a Fringe Field Sensor.
- What was Dune Medical Devices developing with support from the European Union?
- Dune Medical Devices was developing a smart biopsy system for breast tissue, which received funding from the European Union's Horizon 2020 research and innovation program.
- Which investors participated in the July 2017 funding round?
- In July 2017, Dune Medical Devices received funding from Canepa Healthcare and The Kraft Group.
- Which investor led the October 2014 funding round?
- Apax Partners led a funding round for Dune Medical Devices in October 2014, with participation from.